export default function MazdutideOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Mazdutide is a weight loss drug in Phase 3 trials in China &mdash; not approved anywhere, not available through any legitimate channel outside of those trials. It pairs appetite suppression with a direct boost to how much energy the liver burns, which is the mechanistic case for why it may do things that GLP-1-only drugs cannot. The community interest is about watching where obesity pharmacology is heading, not about accessing it now.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Weight Loss Pipeline Watcher &mdash; What Comes After Semaglutide and Tirzepatide</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I keep reading that tirzepatide is the best weight loss drug right now. Is there something in the pipeline that&rsquo;s going to be even better, and is mazdutide one of them?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The glucagon component adds something GLP-1-only drugs don&rsquo;t have</strong><br />Semaglutide and liraglutide work primarily by suppressing appetite. Tirzepatide adds a second signal (GIP) that improves insulin sensitivity and amplifies the GLP-1 effect. Mazdutide takes a different second signal &mdash; glucagon &mdash; that directly increases how much energy the liver burns. In theory, that metabolic acceleration on top of appetite suppression could produce weight loss and liver fat reduction beyond what appetite suppression alone achieves. The early Phase 2/3 data shows roughly 10&ndash;13% weight loss at 24 weeks alongside significant liver fat reduction, which is the signal that distinguishes it.</li>
          <li><strong>The NAFLD/fatty liver angle is the most distinctive clinical case</strong><br />GLP-1-only drugs reduce liver fat partly as a consequence of weight loss. The glucagon receptor activation in mazdutide directly drives hepatic fat oxidation &mdash; the liver burns its own fat stores more actively. This makes it a particularly interesting pipeline drug for metabolic-associated steatohepatitis (MASH, formerly NAFLD), where liver fat is the primary target rather than just a downstream benefit of weight loss.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Mazdutide is not available. Full stop. The trials are in China with predominantly Chinese patient populations, which limits how directly the efficacy and safety data generalizes to other populations. It has no global regulatory clearance, no FDA review, and no licensed distribution channel anywhere outside those trials. Anyone selling it as a research peptide is selling something unverified at unknown quality. Net: worth following as a pipeline signal; nothing to do about it today except wait for proper regulatory development.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; Next-Generation Metabolic Drug Awareness</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve been following the GLP-1 space for performance and body composition. Is mazdutide meaningfully different from tirzepatide for an athlete, or is this just more of the same?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The energy expenditure angle is the interesting performance hypothesis</strong><br />GLP-1 drugs suppress appetite, which can make cutting more sustainable. Tirzepatide adds GIP signaling which has modest effects on adipose metabolism. Mazdutide&rsquo;s glucagon component directly increases resting energy expenditure &mdash; the body burns more at rest. For an athlete trying to cut fat while maintaining performance, a drug that actively increases metabolic rate rather than just reducing intake is a different kind of tool, if the muscle-sparing profile holds up in athlete populations.</li>
          <li><strong>The GLP-1/glucagon combination is a distinct mechanism from GLP-1/GIP</strong><br />Tirzepatide and mazdutide take different second signals. Understanding what glucagon receptor agonism actually does &mdash; increased hepatic glucose output, increased lipolysis, increased energy expenditure &mdash; versus what GIP does is the mechanistic distinction worth understanding. They are not functionally interchangeable dual agonists; the downstream effects are different and the clinical profiles will likely differ meaningfully.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">There is no athlete-specific safety or efficacy data for mazdutide. The glucagon component raises hepatic glucose production, which in a healthy person with functioning glucose regulation is generally handled, but the effects in high-performance athletic contexts are not studied. Glucagon also has catabolic effects that could theoretically complicate muscle preservation during aggressive cuts &mdash; this is an open question, not a solved one. As a pipeline compound with limited trial data, it&rsquo;s too early to evaluate it against tirzepatide for athlete use. Net: interesting mechanism to follow; no actionable data for athletic use today.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Metabolic Biohacker &mdash; GLP-1/Glucagon Dual Agonism and the Next Tier of Obesity Pharmacology</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand how GLP-1/glucagon dual agonism compares mechanistically to GLP-1/GIP (tirzepatide) and GLP-1/GIP/glucagon (retatrutide) in terms of the expected metabolic phenotype.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why it&rsquo;s worth understanding</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Glucagon receptor agonism adds a qualitatively different lever to the metabolic pharmacology</strong><br />GIP co-agonism (tirzepatide) primarily improves insulin sensitivity and adipose metabolism. Glucagon receptor co-agonism (mazdutide, retatrutide) directly increases hepatic fat oxidation and energy expenditure &mdash; mechanisms that GIP does not meaningfully activate. The clinical implication is that glucagon-containing dual agonists may produce greater liver fat reduction independently of weight loss, and potentially greater resting metabolic rate effects. This is the hypothesis the mazdutide MASH data is beginning to test.</li>
          <li><strong>Mazdutide vs. retatrutide illustrates the triple vs. dual agonist design question</strong><br />Retatrutide (Eli Lilly) adds all three receptors: GLP-1, GIP, and glucagon. Mazdutide uses just GLP-1 and glucagon, skipping GIP. Whether the GIP component in a triple agonist produces meaningfully additive benefit over GLP-1/glucagon alone, or simply adds complexity and side effect burden, is a genuinely open pharmacological question. The comparative Phase 3 data between these drug classes will be one of the more informative natural experiments in obesity pharmacology over the next five years.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Mazdutide&rsquo;s 10&ndash;13% weight loss at 24 weeks is notable but the trial populations and endpoints are not directly comparable to SURMOUNT-1 (tirzepatide, 22% at 72 weeks) or TRIUMPH-1 (retatrutide, early data showing ~24%). Trial design, duration, and population differences make cross-trial comparisons rough. The glucagon receptor agonism also raises the question of how hyperglycemia and heart rate effects manifest at various GLP-1/glucagon dose ratios &mdash; optimizing that ratio is a real pharmaceutical engineering challenge. As a China-based pipeline compound with limited international regulatory engagement to date, the timeline to FDA-level evidence is genuinely uncertain. Net: the most interesting mechanistic addition to the GLP-1 landscape after tirzepatide; years away from being relevant to any personal decision.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Mazdutide is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not available &mdash; there is no legitimate access channel outside of Chinese clinical trials</li>
              <li>Not FDA-reviewed &mdash; no global regulatory clearance exists; no Western Phase 3 data yet</li>
              <li>Not comparable to tirzepatide or semaglutide on efficacy at equivalent trial durations &mdash; the data sets are not directly comparable</li>
              <li>Not safe from unverified sources &mdash; anyone selling &ldquo;mazdutide research peptide&rdquo; is selling an uncharacterized compound at unknown quality</li>
              <li>Not a near-term personal decision &mdash; this is pipeline awareness content, not a practical choice available today</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>Adds glucagon receptor agonism to the GLP-1 toolkit &mdash; a mechanistically distinct second signal from tirzepatide&rsquo;s GIP approach</li>
              <li>The MASH/liver fat data is the most distinctive early clinical signal &mdash; hepatic fat oxidation from glucagon co-agonism may be the differentiator</li>
              <li>The GLP-1/glucagon vs. GLP-1/GIP vs. triple agonist comparison will be one of the defining pharmacological questions of the obesity drug field over the next five years</li>
              <li>Illustrates how China-based pharmaceutical development is now generating clinically meaningful obesity pipeline data that the global field is watching</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
